University of South Dakota

USD RED
Dissertations and Theses

Theses, Dissertations, and Student Projects

12-2021

MOLECULAR MECHANISMS UNDERLYING THE SUPPRESSION OF
CARDIOMYOCYTE NECROPTOSIS BY THE COP9 SIGNALOSOME
IN MICE
Megan T. Lewno
University of South Dakota

Follow this and additional works at: https://red.library.usd.edu/diss-thesis
Part of the Molecular Biology Commons

Recommended Citation
Lewno, Megan T., "MOLECULAR MECHANISMS UNDERLYING THE SUPPRESSION OF CARDIOMYOCYTE
NECROPTOSIS BY THE COP9 SIGNALOSOME IN MICE" (2021). Dissertations and Theses. 15.
https://red.library.usd.edu/diss-thesis/15

This Thesis is brought to you for free and open access by the Theses, Dissertations, and Student Projects at USD
RED. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of USD RED. For
more information, please contact dloftus@usd.edu.

MOLECULAR MECHANISMS UNDERLYING THE SUPPRESSION OF
CARDIOMYOCYTE NECROPTOSIS BY THE COP9 SIGNALOSOME IN MICE

By
Megan T. Lewno
B.S., University of South Dakota, 2016
B.B.A., University of South Dakota, 2016

A Thesis Submitted in Partial Fulfillment of
The Requirements for the Degree of
Master of Science

Division of Basic Biomedical Sciences
Basic Biomedical Sciences Program
In the Graduate School
The University of South Dakota
December 2021

COMMITTEE SIG

NATURE PAGE
The members of the Committee appointed to examine
the thesis of Megan T. Lewno
find it satisfactory and recommend that it be accepted.

Chairperson

ii

ABSTRACT
Background: Within a large subset of heart failure, cardiac ubiquitin-proteasome system (UPS)
inadequacy is causative. A vital UPS regulator is the COP9 signalosome (CSN). The CSN holocomplex is
formed by 8 unique protein subunits (COPS1~COPS8) and regulates Cullin-RING ligases via Cullin
deneddylation. Cardiomyocyte-restricted knockout (cko) of Cops8 causes massive cardiomyocyte
necroptosis via the RIPK1-RIPK3-MLKL pathway, resulting in dilated cardiomyopathy (DCM) and
shortened lifespan in mice. CSN’s deneddylase resides in COPS5 and Cops5-cko has not been explored. It
is important to investigate how the necroptotic pathway within cardiomyocytes is activated in Cops8cko mice as cardiomyocyte necroptosis has been shown to play an important role in cardiac
pathophysiology. Protein kinase Cδ (PKCδ) regulates cardiomyocyte survival but its potential
involvement in cardiomyocyte necroptosis remains unknown. To fill these gaps, we conducted the
present study to examine the hypothesis that Cullin deneddylation suppresses cardiomyocyte
necroptosis but PKCδ promotes the activation of cardiomyocyte canonical necroptotic pathway in
Cops8-cko mice.

Methods and Results: Cops8-cko, Cops5-cko, or Cops8+Cops5 double cko (Double-cko) initiated in adult
mice were achieved using a tamoxifen-inducible Cre-LoxP system. Echocardiography performed 21 days
after tamoxifen withdrawal showed no significant difference between 2 control groups: Myh6MerCreMer transgenic mice (MCM) and Cops5-floxed/Cops8-floxed mice. Compared with MCM, all cko
groups displayed DCM, but the severity in the Cops5-cko and Double-cko groups were similarly greater
than that in the Cops8-cko group. Kaplan-Meier survival analyses revealed that the post-tamoxifen
lifespans of Cops5-cko and Double-cko mice (median, 42 days) were comparably shortened but
significantly shorter than that of Cops8-cko mice (81 days). We observed a greater proportion of
cardiomyocytes positive for Evans blue dye uptake and greater increases of myocardial CD45 proteins in
Cops5-cko and double-cko mice than in Cops8-cko mice. Both Cops8-cko and Cops5-cko mice exhibited a
2.5-fold upregulation of myocardial PKCδ. Coupling heterozygous germ-line knockout of PKCδ with
perinatal Cops8-cko decreased the activation of the RIP1-RIP3-MLKL pathway, attenuated cardiac
malfunction, and delayed mouse premature death induced by Cops8-cko.

Conclusions: Cullin-deneddylation activity is required for the CSN to suppress cardiomyocyte
necroptosis; upregulation of PKCδ contributes to activation of the RIPK1-RIPK3-MLKL pathway by Cops8
deficiency in cardiomyocytes in mice.

Advisor: Xuejun Wang, M.D., Ph.D.
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1. INTRODUCTION
1.1. The ubiquitin-proteasome system
The ubiquitin-proteasome system (UPS) is one of the two major protein degradation pathways
in cells. Abnormalities within the UPS have been implicated in a broad spectrum of human
diseases, more recently within cardiac pathophysiology like cardiomyopathies and congestive
heart failure1-4. The UPS consists of ubiquitination and the subsequent proteasome-mediated
degradation of the ubiquitinated protein. Ubiquitination is catalyzed by a specific enzymatic
cascade including ubiquitin (Ub) activating enzyme (E1), Ub conjugating enzyme (E2), and Ub
ligase (E3). This enzymatic cascade will charge and transfer a Ub protein to a substrate protein
molecule that is damaged, misfolded, or otherwise unneeded within the cell. Multiple rounds of
such reactions attach a chain of Ubs to the substrate protein and the polyubuiquitin tag acts as
a signal to the proteasome to degrade the ubiquitinated substrate. The E3 ligase determines
the specificity of substrates in ubiquitination and is a rate-limiting step, which will be discussed
in depth further in the next section. Overall, the benefit of the UPS is that it recycles toxic or
unneeded regulatory proteins into small chains of amino acids that can then be reused.
Upwards of about 80-90% of all proteins will be regulated through the UPS and therefore, there
are broad implications in virtually all signaling pathways within the cell. Protein homeostasis, or
proteostasis, is maintained through highly regulated protein synthesis, folding, trafficking, post
translational modification, localization, and degradation; however, proteotoxic stress refers to
damaged or misfolded proteins and organelles and their effect on the cell. Increased
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proteotoxic stress can result from genetic causes, environmental stressors, the aging process,
etc. and can cause functional changes in the tissue or organ5.
1.2. Cullin-RING ligase, neddylation, and deneddylation
As mentioned above, E3 ligases determine the substrate specificity in ubiquitination and, in
general, polyubiquitination licenses the protein for degradation by the 26S proteasome,
thereby determining whether the substrate protein molecule can be degraded by the UPS.
More than 600 E3 ligases exist in the eukaryotic cell. The largest subset of E3 ligases, Cullin Ring
Ligases (CRLs), account for 419 of the E3 ligases and approximately 20% of the ubiquitindependent degradation of proteins6, 7. CRLs directly allow for a transfer of a charged ubiquitin
from the E2 to the substrate. All CRLs share a similar core structure where the Cullin serves as a
molecular scaffold that binds to an adaptor protein and a substrate receptor module at the Nterminus of the Cullin and a RING protein at the C-terminus of the Cullin. The substrate
receptor module determines the substrate specificity of the CRLs. Once fully assembled, a
ubiquitin-like protein NEDD8 (Neural precursor cell Expressed Developmentally Down-regulated
8) will be covalently attached to a key lysine residue at the C-terminus of the Cullin via a
ubiquitination-like process, known as neddylation. Cullin neddylation activates the CRL. The
reverse process, Cullin deneddylation, is the cleavage of the NEDD8 protein from the CRL and
deactivates the CRL. Cullin neddylation is essential to CRL assembly and activation, while Cullin
deneddylation is essential to CRL disassembly and deactivation. Cullin deneddylation is
performed by the Cop9 signalosome and will be detailed further in the next section. Timely
assembly and disassembly of CRLs are pivotal to maintaining CRL catalytic dynamics and overall
proteostasis.
2

1.3. The COP9 signalosome and its bona fide biochemical activity
The COP9 (COnstitutive Photomorphogenesis 9) signalosome (CSN) was first discovered in the
Arabidopsis thaliana, a small flowering plant, and is highly conserved in eukaryotes, from yeast
to humans and plays a role in a wide variety of signaling pathways like cell cycle progression,
DNA repair, nuclear export, and immune responses8-11. The CSN is a vital ubiquitination
regulator in the UPS and consists of eight canonical protein subunits (COPS1/CSN1 through
COPS8/CSN8). The CSN’s bona fide biochemical activity is as a deneddylase- or deconjugation of
a NEDD8 protein from a neddylated Cullin. Thus, correct functioning of the CSN allows for
regular disassembly of these CRLs when appropriate, which is vital to correct ubiquitination and
the subsequent degradation or signaling fate of an extensive range of cellular substrates as well
as toxic, cytosolic misfolded proteins. For proper CSN biochemical activity, all eight subunits are
required1. In situations where a subunit is depleted, the other subunits are depleted to various
degrees and Cullin deneddylation is impaired, illustrating that the deneddylase activity of the
CSN requires the formation of the CSN holocomplex by the eight subunits. Loss of CSN function
and Cullin deneddylation leads to self-ubiquitination and destabilization of many substraterecognizing adaptors in CRLs and thereby accumulating their substrates (Figure 1)12-15. The
COPS5 subunit contains the deneddylase site of the CSN, but COPS5 only exerts Cullin
deneddylation activity when it is situated in the fully assembled CSN holocomplex consisting of
all eight canonical subunits6, 16.
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Figure 1. A working model for the role of the COP9 Signalosome (CSN) in the regulation of the
catalytic dynamic of Cullin-RING ligases (CRLs). A. Under normal condition, the CSN holocomplex
formed from the 8 unique protein subunits (CSN1 through CSN8) removes the Nedd8 from the
neddylated Cullin, thereby inactivates and dissembles the CRL that has completed ubiquitinating a
substrate protein (Substrate-1) recruited by substrate receptor 1 (SR1), allowing formation of a new
CRL with a new SR (SR2) to recruit a new substrate (Substrate-2) for ubiquitination. B. Defect in the
formation of the CSN holocomplex, such as depletion of a subunit due to genetic mutation, may
increase the abundance of certain species of mini complexes composed of some of the CSN subunits
but reduces or loses the deneddylase activity, impairing Cullin deneddylation; Cullin deneddylation by
the CSN can also be inhibited by small molecules (e.g., CSN5i-3). When Cullin deneddylation is lost,
the exchange of SRs in CRLs will be compromised and as a result, the catalytic dynamic of CRLs will be
stalled, even leading to autoubiquitination and destruction of CRL components (e.g., SR). (Adopted
from Lewno, et al15.)
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1.4. Necroptotic pathways
Many studies have shown that cardiomyocyte death is a major turning point in the genesis of
heart failure17, 18. Severe dysfunction of cellular proteostasis leads to changes in cellular
functioning and in extreme cases leads to cell death19. In a functioning heart, cardiomyocytes
need to withstand high amounts of thermal and mechanical stress and are therefore more
sensitive to cell death if proteostasis is not adequately maintained. Loss of cardiomyocytes in
the form of apoptosis and necrosis can be the tipping point during the progression from various
forms of primary heart disease to heart failure. Accordingly, ablation of many of the CSN
subunits or the CSN holocomplex, either genetically or chemically, has been shown to induce
massive cell death20-24. Recently, it has been found that not all necrosis is accidental, but
multiple forms of highly regulated necrosis are present. Necroptosis, the earliest identified
regulated death receptor-triggered necrosis, is perhaps the most studied thus far. The canonical
necroptotic pathway, the receptor-interacting protein kinase 1 (RIPK1)-RIPK3-MLKL (mixedlineage kinase domain-like protein) pathway, is activated via TNFα ligand binding to the TNFR1
receptor (Figure 2)15. Based on the cellular environment, specifically with the absence of
correct Caspase 8 activity, RIPK1 will act as a molecular checkpoint, where specific
phosphorylated sites will either activate as in the case of Ser166-phosphorylated RIPK1 (pS166RIPK1) or suppress in the case of Ser321-phosphorylated RIPK1 (pS321-RIPK1) in the kinase
activity of RIPK1. With activation of this pathway, activated RIPK1 binds to and phosphorylates
RIPK3, which in turn recruits and phosphorylates MLKL at site Ser345. Ser345-phosphorylated
MLKL (pS345-MLKL) will then translocate to the plasma membrane and oligomerize creating
pores, which allow for the cell membrane to become permeable to extracellular ions and water
5

as well as releasing intracellular contents into the extracellular space, thereby causing
subsequent cell swelling and rupture while also releasing cellular contents that trigger
inflammatory responses. Accordingly, potential links between necroptosis and the catalytic
dynamics of CRLs regulated by the CSN have been postulated but not fully understood16.
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Figure 2. An illustration for the potential signaling events and outcomes after the activation of
TNFR1. The binding of TNFα to TNFR1 induces the formation of a membrane-bound assembly knowns
as Complex I which is associated with the cytoplasmic tail of TNFR1 and contains TRADD, RIPK1,
TRAF2, LUBAC, and cIAP1/2, where LUBAC adds linear ubiquitin chains to RIPK1 and other proteins,
whereas cIAP1/2 catalyze the addition of K63-linked polyubiquitin chains to RIPK1 and other proteins
within Complex I. The ubiquitinated RIPK1 functions as scaffold to recruit NEMO and TAK1, leading to
the activation of NFκB and MAPK pathways, respectively and promotes cell survival and inflammation
(A). Complex I can be transformed into the secondary cytosolic Complex IIa and IIb to signal for
apoptosis (B) or necroptosis (C), respectively. B, Caspase-8 activity in Complex IIa determines
downstream signaling toward an apoptotic outcome and simultaneously prevents necroptosis by
cleaving RIPK1 or RIPK3. C, In Complex IIb, the absence or inactivation of caspase-8 triggers
autophosphorylation of RIPK1, which in turn binds and phosphorylates RIPK3; phosphorylated RIPK3
recruits and phosphorylates MLKL, leading to MLKL’s translocation to the plasma membrane where
MLKL oligomerizes and forms pores, allowing an influx of extracellular ions and water into the cell
that causes cell swelling and rupture, and the release of cellular contents triggers proinflammatory
responses. (Adopted from Lewno, et al15.)
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1.5. Why is it important to study the CSN in the heart?
The UPS is both implicative and causative in a broad spectrum of diseases, more recently within
cardiac pathophysiology. Studying the mechanisms that regulate the UPS, like CRLs and the
CSN, is essential to understanding and pursuing this degradation pathway for promising
therapeutic benefits25-27 Using classic mouse models of arrythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C), others have shown that these hearts have reduced
junctional localization of Cops6, which impacts how desmosome and gap junctions are able to
communicate electrically and form structurally and ultimately destruction of the desmosome
occurs subsequently. They also showed that loss of Cops6 in hearts lead to increased
neddylated CRLs. Down regulation of Cops6 has been found in human hearts with ARVD/C and
down regulation of Cops6 was sufficient to cause ARVD/C in mouse models28, which
mechanistically links dysregulation of the CSN to human heart disease. However, their study did
not look into deneddylation activity, holocomplex levels, or cell death within the Cops6
knockout animals, which will be important.
1.6. Cops8-cko mice provide a valuable model for studying inadequate PQC in cardiac
pathophysiology
Using a perinatal cardiomyocyte-restricted knockout of Cops8 (Cops8-cko) in mice, our lab has
verified that Cullin deneddylation is impaired in cardiomyocytes and that necroptosis is a
mechanistic link between inadequate protein quality control mechanisms and the development
of cardiac pathophysiology20. In the Cops8-cko mice, Cullin deneddylation dysfunction is the
first noticeable impairment. After which, both the UPS and the autophagic-lysosomal pathway
(ALP) become dysfunctional, leading to massive necroptotic cardiomyocyte death via the RIPK18

RIPK3-MLKL pathway, a dilated cardiomyopathy phenotype, and a shortened lifespan20, 29.
Accordingly, even a moderate downregulation of Cops8, using a hypomorphic Cops8 model
causes similar effects22, 30. Hence, our lab has shown that the CSN holocomplex suppresses the
cardiac RIPK1-RIPK3-MLKL necroptotic pathway in vivo29. Using genetic or chemical inhibition of
core signaling proteins in the RIPK1-RIPK3-MLKL pathway, our lab has shown the promising
therapeutic benefit of suppress0ing this inflammatory-type of cell death and subsequent
cardiac pathological remodeling29. Furthermore, the Cops8-cko mouse model offers us a
valuable tool for studying the prevention and effective treatment of cardiomyocyte necroptotic
cell death, which mechanisms are currently poorly understood.
1.7. PKCδ and cardiomyocyte death
Protein kinase Cs (PKC) are an important enzyme family consisting of at least eleven closely
related serine-threonine kinase enzymes encoded by the Prkcd gene31. These PKC enzymes
have a highly conserved carboxy terminal kinase domain with a differing amino terminal
regulatory region32, 33. Once these PKC enzymes are newly synthesized, they remain in a
dormant state and become activated by posttranslational modification at distinct sites by
second messengers, like phorbolesters and phospholipids. Once activated, PKCs will translocate
to membranous sites, like the mitochondria or plasma membrane34, 35. A specific isoform in the
novel group of PKCs, protein kinase C-delta (PKCδ), is expressed in many tissues, but expression
seems to be localized to the atria of the heart with a presence in the ventricles, mostly in the
membrane fraction36. PKCδ is thought to play a role in signaling that stimulates contraction but
has become more notoriously known as a pro-death kinase, playing important roles in the
apoptotic and necroptotic signaling pathway in response to oxidative stress37. Typically, PKCδ is
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a lipid-dependent enzyme that, once activated, phosphorylates substrates in the cytosol;
however, depending on the specific physiological stimuli, like oxidative stress, PKCδ becomes
lipid-independent, changes substrate specificity and is thought to translocate to the
mitochondria to decrease ROS generation by preventing the opening of the transition pore and
activation of KATP channels to allow proteasome activity to continue normally, which will then
degrade PKCδ38, 39. It has also been postulated that the overall levels of PKCδ (and other PKCs)
are regulated by the proteasome during stressful stimuli40. PKCδ, in the presence of oxidative
stress, causes changes in cardiac contraction and has shown to contribute to ventricular
remodeling41. Transient episodes of ischemia activate PKCδ; however, inhibition of PKCδ during
reperfusion of myocardial infarction is cardioprotective42, 43. Identifying therapies that regulate
PKCs have become increasingly popular. Oxidative stress is high during apoptosis and
necroptosis, and PKCδ has been explored in the context of apoptosis, but the relationship
between PKCδ and necroptosis or the RIPK1-RIPK3-MLKL necroptotic pathway is obscure.
1.8. Hypothesis and specific aims
The overarching goal of this project is to aid in the current comprehension of molecular and
cellular mechanisms that lead to heart failure in hopes of finding effective therapeutics. This
project is aimed to 1) compare phenotypic differences between three CSN subunit
cardiomyocyte-restricted knockout models: Cops8-cko, Cops5-cko, a double gene knockout
(Cops8 + Cops5) in vivo. Any shared phenotypes between the models will be implied from the
loss of the Cop9 signalosome holocomplex and Cullin deneddylation. However, differences in
phenotypes are presumably from subunit-specific functions outside of the holocomplex. This
project is also aimed to 2) preliminarily examine the role of PKCδ in the context of
10

cardiomyocyte necroptosis induced by Cops8-cko. This is to test the hypothesis that Cullindeneddylation activity is required for the CSN to suppress cardiomyocyte necrosis and that
upregulation of PKCδ contributes to the activation of the necroptotic pathway.
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2. MATERIALS AND METHODS
2.1. Animal Models
All procedures involving animals were approved by the Animal Care and Use Committee of the
University of South Dakota and conform to the NIH Guide for the Care and Use of Laboratory
Animals. All in vivo studies were performed in age-matched, evenly sexed mice in the C57BL/6J
background (referred to as B6; #000664, The Jackson Laboratory). Two cardiomyocyte specific
Cops subunit knockout models were used: a perinatal knockout and an adult (inducible)
knockout. For perinatal Cops8-cko, we used exactly the same perinatal Cre-LoxP strategy as we
previously reported 20. The mice harboring the Cops8 floxed allele (Cops8FL/FL) were originally
generated by Dr. Wei’s lab44, where the exons 4 through 6 of the Cops8 gene is flanked by two
loxP sites. The Cops8FL/FL mice were crossed with a transgenic mouse expressing the Cre
recombinase driven by the mouse alpha-myosin heavy chain gene promoter directing
expression of Cre recombinase to cardiomyocytes (referred to as αMyHC-Cre or Myh6-Cre; #
018972, The Jackson Laboratory). CSN5 (AKA, Jab1) is encoded by COPS5. Dr. R. Pardi generated
the mouse with a Cops5-floxed allele in which exon 2 is flanked by 2 LoxP sites inserted in the
introns sandwiching exon 2. Cre-mediated recombination effectively removes the exon 2,
resulting in an early frameshift and translation termination 45. This mouse model has since been
successfully used for conditional CSN5 knockout in T cells,45 B cells,46 Schwann cells,47 and
hepatocytes.48 So far, no reported studies have investigated Cops5-cko. We have acquired
Cops5-floxed mice (Cops5flox/flox) from Dr. Pardi for studies proposed here. The same floxed
mice used above were used for the adult, inducible knockouts and will be described in Section
2.2. The PKCδ is encoded by the PRKCD gene. Mice with global knockout of the Prkcd gene
12

(PKCδ-KO) were purchased from The Jackson Laboratories (Stock #028055). PKCδ-KO mice lack
the initiation codon in the exon 2 of Prkcd, resulting in a null allele49. Since homozygous
knockout of Prkcd (Prkcd-/-) caused adverse effects (data not shown), heterozygous PKCδ-KO
(Prkcd+/-) was used for the PKCδ-KO rescue experiments, in which perinatal Cops8-cko was
introduced into Prkcd+/- and Prkcd+/+ background via cross-breeding and littermates were used
for comparisons.
2.2. Tamoxifen Treatment to Induce CKO in Adult Mice
Induction of cardiomyocyte-specific knockout of Cops8 (Cops8-cko), Cops5 (Cops5-cko), or both
genes (a double knockout of Cops8 and Cops5 henceforth referred to as Double-cko) in adult
mice was achieved using a tamoxifen-inducible Cre-LoxP system where the transgenic (TG)
mutant estrogen receptor sandwiched Cre (MerCreMer) was used as reported by others50.
MerCreMer (MCM) is sequestered in the cytoplasm as it is not sensitive to the endogenous
estrogen, but it can be bound by tamoxifen and thereby translocated from the cytoplasm to the
nucleus where the MCM exerts its Cre recombinase activity. Both of Cops8- and Cops5-floxed
mouse models were crossed with a TG mouse expressing the MCM driven by the mouse alphamyosin heavy chain gene promoter [B6.FVB(129)-Tg(Myh6-Cre/Esr1*)1Jmk/J; also known as αMHCMerCreMer or Myh6-MerCreMer] (JAX stock #005650; Jackson Labs)51. At two months of age,
when physiological development is mostly complete, regular chow was switched out with a
chow containing tamoxifen citrate (40 mg/KG; TD.130859 Envigo) and the mice were fed ad
libitum for 14 days. Neither control nor experimental animals died from this tamoxifen
administration regime. A schematic is presented below to show the timeline of treatments and
experimental procedures performed (Figure 3).
13

Figure 3. A schematic for the design of experiments using the tamoxifen induced cko in adult mice.
All adult mice were subjected to 14 days of tamoxifen administration via chow as illustrated. After
tamoxifen administration, mice were subjected to EBD injections and subsequent perfusion fixation
and tissue sampling for confocal microscopy (A), tissue sampling for biochemical analysis (B), or
echocardiography and subsequent Kaplan-Meier survival analysis (C).

2.3. Western Blot Analysis
Western blotting was performed as previously described20. In brief, proteins were extracted
from frozen ventricular myocardial tissues, homogenized in sampling buffer (1.0M Tris-HCl (pH
6.8), 10% SDS, and 10% glycerol) containing a cocktail of protease inhibitors (#T-2496, AG.
Scientific, San Diego, CA) to inhibit subsequent protein degradation, centrifuged for 10 minutes
at 12,000g at 4°C, and supernatant was then collected. Protein concentration was measured
using the bicinchoninic acid (BCA) assay (#23225, Themo Fisher Scientific). Polyacrylamide gels
were made in house and 2,2,2-trichloroethanol (#139445000 , ACROS Organics) was added to
the resolving gel for later florescent imaging of protein loading52. Equal amounts of protein
sample were resolved by SDS-PAGE, transferred to PVDF membrane, and then membrane was
blocked for 1 hour (in 5% milk), washed 3 times in PBST (TBST if phosphorylated protein) for 5
minutes, incubated with appropriate primary antibodies for 12 hours on rocker (overnight in 4°
fridge) (primary antibodies used are listed in Table 1), washed 3 times in PBST/TBST for 5
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minutes, incubated with horseradish peroxidase–conjugated (HRP) secondary antibodies
(Mouse: 115-035-003, Rabbit: 111-035-003, Goat: 305-035-003, Jackson ImmunoResearch) for
1 hour, washed 3 times in PBST/TBST for 5 minutes, and Chemiluminescence (34578, Thermo
Fisher Scientific) substrate was added to membrane and membrane was imaged via a
ChemiDoc MP Imaging System (Bio-Rad). The signal was quantified and normalized to loading
control, Stain-Free total proteins, using Image Lab 6.0 software (Bio-Rad).
Table 1. Primary Antibody List
Primary Antibody

Vendor

Catalog Number

Dilutions Used

CSN5
CSN8
CD45
PKCδ
Total RIPK1
Total RIPK3
Total MLKL
pS166-RIPK1
pS321-RIPK1
pS345-MLKL

Bethyl Laboratories
Santa Cruz
R&D Systems
Santa Cruz
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling

A300-014A
sc-47976
AF114
sc-8402
3493s
14401
37705
31122S
83613S
37333s

1:1000
1:1000
1:500
1:1000
1:1000
1:1000
1:1000
1:500
1:500
1:500

2.4. Evans Blue Dye (EBD) Uptake Assay and Confocal Microscopy
EBD uptake assay was performed as previously described20, 53. In brief, EBD (#314-13-6,
MilliporeSigma) solution (10 mg/mL dissolved in normal saline) was injected intraperitoneally
(100 g/g of body weight). 12 hours later, the mouse was anesthetized, and the circulatory
system was slowly perfused with both PBS to clear remaining blood and then freshly made 4%
paraformaldehyde (PFA) to fix the tissue. Atria and fat were removed from heart and the
ventricular myocardium was placed in 4% PFA for 12 hours on rocker (overnight in 4° fridge),
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washed with PBS and then subsequently placed in 40% sucrose for 12 hours on rocker
(overnight in 4° fridge). The myocardium was then embedded in O.C.T. (#23-730-571, Fisher
Scientific) and quickly frozen on the surface of methanol/dry ice. 7m cryosections were
collected and stained with phalloidin-fluorescein conjugate (#20478, Cayman Chemicals) and
DAPI fluoromount (#0100-20, Southern Biotech) to fluoresce F-actin (cell membrane) and
nuclei, respectively. Multiple confocal images were taken at X20 magnification and merged into
one final image. The excitation wavelength used was 499 and emission wavelength used was
680nm. The total staining of auto fluorescent EBD positive cells, red, was then normalized to a
control, the total staining of cell membrane, green, from representative images from 4
mice/genotype.
2.5. Echocardiography
The 2D-guided M-Mode echocardiography was performed as previously described20, 54. In brief,
mice were anesthetized by inhalation of isoflurane (4.0% for induction and 1.5~2% for
maintenance) via a nose cone. Chest hair was removed using Nair and transthoracic
echocardiograph was recorded using the Vevo2100 echocardiography system (Visual Sonics)
with a 32–56 MHz transducer (MS550s). A 2D short axis view was recorded at the papillary
muscle level. The left ventricle morphometric and functional parameters were analyzed later
using Vevo LAB 5.6.0 software (Visual Sonics). Derived parameters were calculated using the
following calculations stroke volume (SV) equals end diastolic volume minus end systolic
volume, Fractional Shortening (FS) equals end-diastolic left ventricular internal diameter minus
end-systolic left ventricular internal diameter divided by end-diastolic left ventricular internal
diameter times 100, Ejection Fraction (EF) equals SV divided by end diastolic volume times 100,
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and Cardiac Output (CO) equals stroke volume times heart rate.
2.6. Statistical analysis
Unless otherwise indicated, data of continuous variables are presented as scatter dot plots with
mean ± SEM superimposed. Differences among three or more groups were evaluated using
one-way ANOVA followed by Tukey test for pairwise comparisons. A p-value < 0.05 was
considered statistically significant. Kaplan-Meier survival curves significance testing was done
using Log-Rank (Mantel-Cox) test between two groups. If more than two groups were being
analyzed in a Kaplan-Meier survival curve, the p-value significance level was adjusted using
Bonferroni corrected p-value thresholds to correct for multiple statistical testing between
groups. The GraphPad Prism software (Version 9.2; GraphPad Software, San Diego, CA 92108)
was used for statistical analysis.
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3. RESULTS
3.1. Verification of tamoxifen-inducible cardiomyocyte-specific knockouts
The CSN requires all the eight canonical protein subunits for the holocomplex formation and
proper CSN deneddylase functioning8. Although much is known about CSN subunit knockout
phenotypes in certain tissue types, the different subunits’ knockout effect on the heart is
largely unknown. To elucidate this, three mouse models of CSN subunit cardiomyocyte-specific
knockout using a tamoxifen inducible Cre-LoxP system were tested to see general effects on the
heart. Western blot analyses for Cops8 and Cops5 in the ventricular myocardial samples
revealed that all knockouts show a significant downregulation of the protein respective to the
gene directly knocked out (i.e., Cops8-cko mice have a 70% decrease in CSN8 protein levels, pvalue = 1.9 x 10-11; Cops5-cko mice have a 62% decrease in CSN5 protein levels, p-value = 2.8 x
10-11; and Double-cko mice have an 87% decrease in CSN8 and a 60% decrease in CSN5 protein
levels, p-value = 1.9 x 10-12, p-value = 5.1 x 10-11) as compared with MCM Cre controls (Figure
4). When one subunit of this complex is downregulated, the other CSN subunits will be
destabilized and subsequently degraded by the UPS55. This expected phenomenon is present in
these models as well (i.e., Cops8-cko mice have a 49% decrease in CSN5 protein levels, p-value
= 9.1 x 10-10; Cops5-cko mice have a 55% decrease in CSN8 protein levels, p-value = 6.2 x 10-10
(Figure 4). These results indicate that each respective knockout model was achieved efficiently.
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Figure 4. Western blot analyses for myocardial CSN8 and CSN5 in Cops8-cko, Cops5-cko, and
Double-cko mice at 3 weeks after tamoxifen chow withdrawal. A, representative western blot
images of the indicated proteins- CSN8, CSN5, and a stain-free total protein image used as a loading
control (L.C.). B and C, the pooled densitometry data for CSN8 (B) and CSN5 (C). Each dot represents a
mouse. N = 4 mice per group (2 males, 2 females). **p<0.001, ***p<0.0001.
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3.2. Cops5-cko and Double-cko mice develop dilated cardiomyopathy before Cops8-cko
Knocking out of the smallest and non-catalytic CSN subunit, Cops8, in mice causes extensive
cardiomyocyte necroptosis, dilated cardiomyopathy, and shortened lifespan in mice20. At five
weeks post tamoxifen treatment, a comparison of phenotypic differences between three CSN
subunit cardiomyocyte-restricted knockout models: Cops8-cko, Cops5-cko, a Double-cko in vivo
showed that Cops5-cko and Double-cko mice develop dilated cardiomyopathy before
symptomology appears in Cops8-cko. As compared with MCM-Cre controls, all cko groups have
reduced Ejection Fraction (EF) and Fractional Shortening (FS) indicative of impaired LV function
(MCM-Cre controls: mean EF: 43.7%, FS: 21.6%; Cops8-cko: EF: 33.2%, p=8.4 x 10-4, FS: 16.1%,
p=9.8 x 10-4; Cops5-cko: EF: 17%, p=1.6 x 10-10, FS: 7.7%, p=1.6 x 10-10; Double-cko: EF: 16.4%,
p=1.6 x 10-10, FS: 7.5%, p=1.6 x 10-10) (Figure 5). However, when directly compared with Cops8cko, the Cops5-cko and Double-cko mice have significantly lower EF, FS, Stroke Volume (SV),
Cardiac Output (CO), Left Ventricular Posterior Wall End Systole (LVPW;s), and Left Ventricular
Posterior Wall End Diastole (LVPW;d) indicating impaired LV function and thinning of cardiac
walls consistent with a dilated cardiomyopathy phenotype (Figure 5). All echocardiographic
parameters are shown in Table 2. The results of these echocardiograms show that Cops5-cko
and Double-cko have a worsening phenotype than Cops8-cko in vivo.
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Figure 5. Key parameters of the M-mode echocardiography recorded 3 weeks after tamoxifen chow
withdrawal. Shown are Ejection Fraction (EF; A), Fractional Shortening (FS, B), Stroke Volume (SV, C),
Cardiac Output (CO, D), End-Systolic Left Ventricular Posterior Wall Thickness (LVPW;s, E), and EndDiastolic Left Ventricular Posterior Wall Thickness (LVPW;d, F). Each dot represents a mouse. MCM
CTL (N=36), Cops8-cko (19), Cops5-cko (14), Double-cko (19); equal numbers of each sex were used.
*p<0.01, **p<0.001, ***p<0.0001; n.s., not significant.
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Table 2. Comparison of echocardiographic parameters 3 weeks after tamoxifen chow
withdrawal
MCM CTL
(N=36)

Cops8-cko
(N=19)

Cops5-cko
(N=14)

Double-cko
(N=19)

Body Weight (g)

27.8 ± 3.9

28.2 ± 5.9

26.3 ± 3.5

24.7 ± 3.7

Heart Rate (BPM)

429.1 ± 48.4

442.3 ± 64.9

431.6 ± 68.5

435.5 ± 58.2

LVID;s (mm)

3.4 ± 0.3

4.1 ± 0.8***

4.6 ± 0.6***

4.5 ± 0.6***

LVID;d (mm)

4.4 ± 0.3

4.8 ± 0.6**

4.9 ± 0.5**

4.9 ± 0.5**

ESV (uL)

49.7 ± 11.5

77.5 ± 37.4**

97.3 ± 28.7***

95.3 ± 27.1***

EDV (uL)

87.9 ± 14.5

110.9 ± 32.3**

115.9 ± 27.0**

112.6 ± 25.7**

LV Mass (mg)

111.2 ± 27.6

140.5 ± 37.3**

115.1 ± 20.9

110.5 ± 36.8

LVAW;s (mm)

0.68 ± 0.13

0.71 ± 0.14

0.60 ± 0.09

0.56 ± 0.15*, ##

LVAW;d (mm)

0.68 ± 0.13

0.71 ± 0.14

0.60 ± 0.09

0.56 ± 0.15*, ##

LVPW;s (mm)

0.80 ± 0.17

0.83 ± 0.18

0.64 ± 0.07**, ##

0.62 ± 0.14***,
###

0.59 ±

0.06#

0.60 ± 0.14##

LVPW;d (mm)

0.67 ± 0.11

0.72 ± 0.13

EF (%)

43.7 ± 6.8

33.2 ± 14.3***

17.0 ± 6.8***, ###

16.4 ± 8.8***, ###

FS (%)

21.6 ± 4.0

16.1 ± 7.5***

7.7 ± 3.2***, ###

7.5 ± 4.2***, ###

SV (uL)

38.2 ± 7.6

33.4 ± 11.1

18.5 ± 5.4***, ###

17.4 ± 7.5***, ###

CO (mL/min)

16.4 ± 3.7

14.8 ± 5.5

7.5 ± 2.4***, ###

7.6 ± 3.8***, ###

Equal numbers of each sex were used. Mean ± SD; *p<0.01, **p<0.001, ***p<0.0001 compared

to MCM CTL. #p<0.01, ##p<0.001, ###p<0.0001 compared to Cops8-cko.
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Figure 6. Representative M-mode echocardiographs recorded 3 weeks after tamoxifen chow
withdrawal.
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3.3. Cops5-cko and Double-cko mice have more severely shortened lifespans as than Cops8cko
Kaplan-Meier survival analyses revealed shortened lifespans for all cko groups as compared to
the MCM-Cre control group, where no animals from the MCM-Cre control group died during
the timeframe analyzed. However, the post-tamoxifen lifespans of Cops5-cko and Double-cko
mice, although comparable to each other (median=42 days for both), were both significantly
shorter than the post-tamoxifen lifespans of the Cops8-cko mice (median=81 days; p<0.0001,
Log-Rank test; Figure 7). These data show that the Cops5-cko and Double-cko mice have

significantly decreased lifespan as compared to Cops8-cko, consistent with the difference in the
severity of cardiomyopathy in these mice.

Figure 7. Kaplan Meier Survival Curves for Cops8-cko, Cops5-cko, and Double-cko mice. N for each
genotype is followed in parenthesis of legend. Equal numbers of each sex were used.
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3.4. Cops5-cko and Double-cko mice have more extensive cardiomyocyte necrosis as
compared to Cops8-cko
Necrosis, a highly pro-inflammatory cell death, is morphologically distinct from apoptosis56. Cell
membrane permeability and inflammation are important pathological events indicative of
necrosis. In accordance with this, we observed about a 2.5-fold increase in the number of
cardiomyocytes positive for Evans blue dye (EBD) uptake in Cops5-cko and Double-cko mice
than in Cops8-cko or the MCM-Cre control mice, indicative of increased membrane
permeability (Figure 8). High magnitude images were taken to verify that the dye was being up
taken into the cells especially cardiomyocytes (Figure 9). We also observed about a 3.0-fold
increase in the amount of myocardial CD45 proteins, which is a marker for leukocyte
infiltration, in Cops5-cko and Double-cko mice than in Cops8-cko or the MCM-Cre control mice
(Figure 10). These results, taken together, indicate that Cops5-cko and Double-cko mice have
more extensive cardiomyocyte necrosis as compared to Cops8-cko.
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Figure 8. EBD uptake assays in Cops8-cko, Cops5-cko and Double-cko mice. A, representative images
of each ventricular tissue ring were reconstructed (x20 magnification) and used for quantification of
EBD-positive area (red) and Alexa488-conjugated phalloidin to identify cardiomyocytes (green) and B,
the pooled densitometry data. Mice collected 3 weeks after tamoxifen chow withdrawal. Each dot
represents a mouse; N = 4-5 mice per group (2 males and 2 females). One-way ANOVA followed by the
Tukey test for pairwise comparisons. **p<0.001; n.s., not significant. Scale bar=0.4mm.
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Figure 9. Representative high magnification micrographs of EBD uptake assays in Cops8-cko, Cops5cko and Double-cko mice. Representative images from ventricular tissue section to show the number
of EBD-positive area (red), Alexa488-conjugated phalloidin to identify cardiomyocytes (green), and DAPI
to identify nuclei (blue). Scale bar=10µm.
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Figure 10. Cops5-cko and Double-cko mice showed increased CD45 proteins in the
myocardium. A, representative blots are shown for CD45+ and a stain-free total protein
image used as a loading control (L.C.) and B, the pooled densitometry data. Mice collected 3
weeks after Tamoxifen chow withdrawal. Each dot represents a mouse; N = 4 (2 males, 2
females) mice per group; one-way ANOVA followed by the Tukey test for pairwise
comparisons. *p<0.01; n.s., not significant.
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3.5. Increased myocardial PKCδ protein levels in both Cops8-cko and Cops5-cko mice
The pro-cell death enzyme PKCδ has been shown to be upregulated in different cardiac
pathological models. Western blot analyses show that both Cops8-cko and Cops5-cko mice
exhibit a similar 3.5-fold upregulation of myocardial PKCδ compared with the MCM control
group (Cops8-cko vs. MCM, p=1.2 x 10-3; Cops5-cko vs. MCM, p=7.0 x 10-4; Figure 11). These
results indicate that PKCδ is upregulated in both Cops8-cko and Cops5-cko mouse models.

Figure 11. Western blot analysis for myocardial PKCδ at 3 weeks post tamoxifen withdrawal. A,
representative images are shown for PKCδ and a stain-free total protein image used as a loading control
(L.C.). B, the pooled densitometry data. Mice collected 3 weeks after tamoxifen chow withdrawal. Each
dot represents a mouse; N = 4 (2 males, 2 females) mice per group; one-way ANOVA followed by the
Tukey test for pairwise comparisons; **p<0.001, ***p<0.0001.
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3.6. PKCδ haploinsufficiency attenuated dilated cardiomyopathy in Cops8-cko mice
PKCδ is encoded by the PRKCD gene57. Other studies have shown that PKCδ inhibition is
cardioprotective due to inhibition of apoptosis and necrosis58, 59. To determine the role of PKCδ
upregulation in the pathophysiology of Cops8-cko, we cross-bred mice with perinatal Cops8-cko
with mice with heterozygous Prkcd knockout (Prkcd+/-), analyzed the phenotypic difference
between the resultant littermate Cops8-cko::Prkcd+/+ and Cops8-cko::Prkcd+/- mice, and
obtained findings to be reported in the following subsections.
3.6.1 PKCδ haploinsufficiency attenuates premature death seen in Cops8-cko mice
Kaplan-Meier survival analyses revealed that PKCδ haploinsufficiency significantly increased
lifespan in mice with perinatal Cops8-cko (Figure 12). The lifespans of perinatal Cops8cko::Prkcd+/+ mice (median lifespan=23 days) were significantly shorter as compared to the Cre
CTL group (p=4.3 x 10-10), where no animals from the Cre CTL group died during the timeframe
analyzed. However, the lifespans of Cops8-cko::Prkcd+/- (median survival: 26 days) were 11%
longer than that of the Cops8-cko::Prkcd+/+ (p=0.04). These results indicate that PKCδ
haploinsufficiency attenuates the premature death seen in Cops8-cko mice.
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Figure 12. PKCδ haploinsufficiency attenuates premature death seen in perinatal Cops8-cko mice. N
for each genotype is followed in parenthesis of legend; equal numbers of each sex used. P=0.04, Cops8cko::Prkcd+/+ vs. Cops8-cko::Prkcd+/-; Log-Rank (Mantel-Cox) test.

31

3.6.2 PKCδ haploinsufficiency attenuates cardiac malfunction induced by Cops8-cko
To determine the impact of PKCδ deficiency on cardiac functioning within the Cops8-cko mouse
model, echocardiography was performed at both 2 and 3 weeks of age for the Cre CTL, the
Cops8-cko::Prkcd+/+, and the Cops8-cko::Prkcd+/- groups. At 2 weeks of age, both Cops8cko::Prkcd+/+ and Cops8-cko::Prkcd+/- groups showed increased end-systolic and end-diastolic LV
diameters and reduced ejection fraction and fractional shortening, indicating impaired LV
function consistent with dilated cardiomyopathy (Figure 13). However, Cops8-cko::Prkcd+/- have
significantly thicker cardiac walls and increased cardiac mass. Stroke volume, cardiac output
and end-diastolic volume (EDV) were all significantly greater in the Cops8-cko::Prkcd+/- as
compared to the Cops8-cko::Prkcd+/+, which becomes more pronounced at 3 weeks of age,
showing that the Cops8-cko::Prkcd+/- are better able to compensate (Figure 13). A complete list
of echocardiographic parameters is shown in Table 3. The results from this echocardiography
shows that Cops8-cko::Prkcd+/- have increased cardiac wall thickness and overall cardiac mass,
which is better able to fill appropriate preload volumes leading to increased stroke volume and
cardiac output. Overall, this echocardiography data indicates that PKCδ insufficiency is able to,
to a certain degree, attenuate cardiac malfunction induced by the Cops8-cko.
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Figure 13. PKCδ haploinsufficiency attenuates cardiac malfunction seen in Cops8-cko mice.
A – F, M-mode echocardiography parameters: End-Systolic Left Ventricular Posterior Wall Thickness
(LVPW;s/BW, A), End-Diastolic Left Ventricular Posterior Wall Thickness (LVPW;d/BW, B), LV Mass (LV
Mass/BW, C), End-Diastolic Volume (EDV, D), Stroke Volume (SV, E), Cardiac Output (CO/BW, F). All
parameters were normalized to body weight. Each dot represents a mouse; equal numbers of each
sex were used. *p<0.01, **p<0.001, ***p<0.0001.
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Table 3. M-mode echocardiography data from the Prkcd+/- rescue experiment
2 Weeks of Age

3 Weeks of Age

Cre CTL
(N=59)

Cops8cko::Prkcd+/+
(N=15)

Cops8cko::Prkcd+/(N=17)

Cre CTL
(N=46)

Cops8cko::Prkcd+/+
(N=11)

Cops8cko::Prkcd+/(N=7)

Body Weight
(g)

6.2 ± 1.2

6.5 ± 1.1

6.3 ± 1.1

7.3 ± 1.7

8.0 ± 1.2

7.2 ± 0.4

Heart Rate
(BPM)

386.6 ±
57.0

424.8 ± 42.1

392.8 ± 36.8

401.3 ±
44.1

403.6 ± 36.9

381.6 ± 47.8

LVID;s/BW
(mm/g)

0.38 ±
0.06

0.51 ± 0.11***

0.55 ± 0.09***

0.39 ±
0.07

0.58 ± 0.12***

0.64 ± 0.11***

LVID;d/BW
(mm/g)

0.49 ±
0.07

0.58 ± 0.11***

0.64 ± 0.08***

0.49 ±
0.09

0.63 ± 0.11***

0.70 ± 0.09***

ESV/BW
(uL/g)

3.1 ± 0.7

6.9 ± 2.3***

8.1 ± 2.9***

4.2 ± 1.0

12.7 ± 4.0***

14.2 ± 4.5***

EDV/BW
(uL/g)

5.6 ± 0.8

9.1 ± 2.1***

11.0 ± 2.9***, ##

6.9 ± 1.2

14.0 ± 3.9***

17.3 ± 4.6***, #

LV Mass/BW
(mg/g)

4.8 ± 0.9

6.6 ± 1.9***

8.5 ± 2.5***, ##

5.2 ± 0.8

8.8 ± 2.0***

9.8 ± 3.7***

LVAW;s/BW
(mm/g)

0.071 ±
0.015

0.067 ± 0.016

0.076 ± 0.019

0.061 ±
0.018

0.052 ± 0.010

0.050 ± 0.012

LVAW;d/BW
(mm/g)

0.065 ±
0.012

0.063 ± 0.015

0.070 ± 0.018

0.057 ±
0.018

0.052 ± 0.010

0.049 ± 0.012

LVPW;s/BW
(mm/g)

0.075 ±
0.016

0.066 ± 0.016

0.078 ± 0.022

0.063 ±
0.021

0.053 ± 0.011

0.054 ± 0.011

LVPW;d/BW
(mm/g)

0.064 ±
0.009

0.060 ± 0.012

0.073 ± 0.020*, #

0.054 ±
0.011

0.052 ± 0.010

0.051 ± 0.009

EF (%)

46.5 ± 5.5

26.4 ± 9.5***

28.7 ± 10.0***

40.2 ±
6.6

13.7 ± 10.4***

19.1 ± 8.7***

FS (%)

22.5 ± 4.4

12.1 ± 4.7***

13.3 ± 5.0***

18.8 ±
3.9

7.8 ± 5.5***

8.8 ± 4.3***

SV (uL)

2.6 ± 0.6

2.2 ± 0.4*

3.0 ± 0.6*, ###

2.7 ± 0.5

1.3 ± 0.5***

3.1 ± 0.7###

CO (mL/min)

1.0 ± 0.2

0.9 ± 0.2*

1.2 ± 0.2*

1.1 ± 0.2

0.5 ± 0.2***

1.2 ± 0.2###

Parameters normalized to body weight are LVID;s, LVID;d, ESV, EDV, LV Mass, LVAW;s, LVAW;d, LVPW;s,
LVPW;d. Equal numbers of each sex were used. Mean ± SD; *p<0.01, **p<0.001, ***p<0.0001 compared
to Cre CTL; #p<0.01, ##p<0.001, ###p<0.0001 compared to Cops8-cko::Prkcd+/+.
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3.6.3 PKCδ haploinsufficiency suppresses the activation of the necroptotic pathway induced
by Cops8-cko in mice
We have previously shown that cardiomyocyte necrosis induced by Cops8-cko belongs to
necroptosis that is mediated by the RIPK1-RIPK3-MLKL pathway60. To test whether
heterozygous PKCδ knockout alters the induction of the canonical necroptotic pathway by
Cops8-cko, we collected ventricular myocardium from mice of the Prkcd+/- rescue
experiment at 3 weeks of age and performed western blot analyses for main proteins of the
RIPK1-RIPK3-MLKL pathway. As compared to Cre CTL, Cops8-cko::Prkcd+/+ mice exhibit
significant upregulation of total Ripk1 (2.7-fold; p=9.8 x 10-4), total Ripk3 (1.6-fold; p=1.1 x
10-4), total MLKL (3.9-fold; p=6.0 x 10-5), pS166-RIPK1 (1.7-fold; p=0.016 ), and pS345-MLKL
(1.6-fold; p=1.7 x 10-3), consistent with activation of the canonical necroptotic pathway. As
compared to Cre CTL, Cops8-cko::Prkcd+/- exhibited trends of upregulation of these
necroptotic proteins, but the differences are not statistically significant. As compared to
Cops8-cko::Prkcd+/+, Cops8-cko::Prkcd+/- exhibited a significant decrease in total Ripk3 (25%; p=0.046), total MLKL (-85%; p=0.016), and pS345-MLKL (-19%; p=0.047) and a trending
decrease in pS166-RIPK1 (-28%; p=0.35). However, Cops8-cko::Prkcd+/- did exhibit a
significant upregulation of Ser321-phosphorylated RIPK1 (pS321-RIPK1) (3.5-fold; p=1.1 x
10-4) (Figures 14 and 15), which is known to serve as a checkpoint and inhibit the RIPK1
kinase and cause suppression of the necroptotic pathway61.
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Figure 14. Western blot analysis for the indicated proteins within the RIPK1-RIPK3-MLKL pathway.
Shown are representative images of the western blots for myocardial levels of the indicated proteins.
Total RIPK1, pS166-RIPK1, pS321-RIPK1, total RIPK3, total MLKL, pS345-MLKL, PKCδ, and CSN8 were
immunoprobed in ventricular myocardial samples collected at 3 weeks of age. The image from StainFree Total Protein imaging that was used as the loading control is shown immediately underneath the
Western blot images that were derived from the gel imaged. Each lane represents a mouse; N > 4 mice
per group; equal numbers of each sex were used.
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Figure 15. Statistical analysis for the western blot analyses illustrated in Figure 14. Shown are the
pooled densitometry data for total RIPK1 (A), pS166-RIPK1 (B), pS321-RIPK1 (C), total Ripk3 (D), total
MLKL (E), pS345-MLKL (F), PKCδ (G), and Cops8 (H). All proteins probed were normalized to Stain-Free
Total Proteins. Each dot represents a mouse; N > 4 mice per group, equal numbers of each sex were
used; one-way ANOVA followed by the Tukey test for pairwise comparisons. *p<0.01, **p<0.001,
***p<0.0001.
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4. DISCUSSION
Among the eight canonical subunits of the CSN, only Cops8 and Cops6 have been investigated
in the heart with conditional gene targeting approaches20, 28. Mice with either prenatal or adult
Cops8-cko displayed massive cardiomyocyte necrosis20, 22, but it remains undescribed whether
cardiomyocyte necrosis occurs in the Cops6-cko mice28. Hence, we induced and verified three
cardiomyocyte-specific CSN knockout mouse models, Cops8-cko, Cops5-cko, and Cops8+Cops5cko (Double-cko), to determine if cardiomyocyte necrosis also can be caused by ablation of
another CSN subunit. This study revealed that the Cops5-cko and the Double-cko mice develop
comparably massive cardiomyocyte necrosis, dilated cardiomyopathy, and a reduced lifespan
that are qualitatively similar to the ultimate phenotypes of Cops8-cko mice; however, they
appear seemingly earlier in Cops5-cko and Double-cko mice than in Cops8-cko. Furthermore,
within the Cops8-cko and Cops5-cko, we noticed a marked upregulation of myocardial PKCδ.
More importantly, the genetic ablation of the PKCδ upregulation significantly blunted the
activation of the RIPK1-RIPK3-MLKL necroptotic pathway, attenuated cardiac malfunction, and
delayed the premature death induced by Cops8-cko in mice. Hence, this study provides
compelling evidence that Cullin-deneddylation activity is required for the CSN to suppress
cardiomyocyte necrosis and demonstrates for the first time that PKCδ plays a crucial mediating
role in the induction of cardiomyocyte necroptosis via the canonical pathway by COPS8
deficiency. These discoveries provide not only new mechanistic insight into the physiological
requirement of the CSN for cardiomyocyte survival but also shine new light on the molecular
links between perturbation of cardiac proteostasis and the genesis of heart failure, both of
which have extremely important clinical implications.
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4.1. Cullin-deneddylation activity is required for the CSN to suppress cardiomyocyte necrosis
We have shown that Cops5-cko and Double-cko mice develop dilated cardiomyopathy before
symptomology is apparent in Cops8-cko as demonstrated by key echocardiographic
parameters. We have also shown that Cops5-cko and Double-cko mice have more severely
shortened lifespans and have more extensive cardiomyocyte necrosis as compared to Cops8cko. The shared phenotype between these three models is likely due to loss of the CSN and
subsequent Cullin deneddylation activity, which leads to cardiomyocyte necrosis in all three
models. The current link between Cops/CSN deficiency and activation of the RIPK1-RIPK3-MLKL
necroptotic pathway remains unclear, but inadequate protein quality control mechanisms offer
exciting, plausible candidates. Our lab has verified that Cullin deneddylation is impaired in
cardiomyocytes and that necroptosis is a mechanistic link between inadequate protein quality
control mechanisms and the development of cardiac pathophysiology in Cops8-cko mice20. The
Cops8-cko and Cops5-cko will be valuable models for studying the necrosis pathway in
cardiomyocytes as well as finding potential therapeutics for the treatment of cardiovascular
diseases.
4.2. Upregulation of PKCδ contributes to activation of the necroptotic pathway by Cops8
deficiency in cardiomyocytes.
Cops8-cko and Cops5-cko mice both showed a 3.5-fold upregulation of the myocardial PKCδ
protein, which has become known as a pro-death kinase. We have also demonstrated that
PKCδ haploinsufficiency attenuated the dilated cardiomyopathy phenotype seen in Cops8-cko
mice by increasing survival by 11%, by improving cardiac functioning of echocardiographic
parameters such as stroke volume and cardiac output, and by suppressing the necroptotic
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pathway that is typically induced by Cops8 deficiency. Using a genetic approach to rescue
Cops8-induced necroptosis, we have shown that PKCδ is contributing to activation of the
necroptotic pathway in a mechanistic fashion that remains to be elucidated. It is unclear
whether 1) PKCδ is playing its role more upstream, such as interacting directly with and
upregulating TNFα in a feed-forward manner and by subsequent promotion of proinflammatory
responses and reduces injury to cardiomyocytes independent of the RIPK1-RIPK3-MLKL
pathway or is 2) PKCδ serving as a kinase and directly contributing to the phosphorylation of
the specific phosphosites in RIPK1 and RIPK3 that are known to activate this necroptotic
pathway, pS166-RIPK1 for example. Cell culture experiments done in smooth muscle cells offer
some insight that PKCδ is playing an important role in chemokine expression as well as
contributing to necroptosis via TNFα-RIPK1-RIPK3-MLKL pathway by transcriptional regulation
of RIPK3 expression in smooth muscle cells62. However, there seems to be cell-specific functions
so deciphering how PKCδ contributes to activation of the necroptotic pathway in
cardiomyocytes remains to be answered.
4.3. Significance and Clinical Implications
Abnormalities within the UPS and ALP have been implicated in a wide spectrum of disease,
lately within cardiovascular diseases that progress to heart failure63, 64. This study directly adds
to the literature of insufficient protein quality control and the pathogenesis of heart failure, to
which current mechanistic insights are widely obscure. The Cops8-cko model is known to cause
widespread and massive cardiomyocyte necrosis; however, this study shows the biological
impact of inhibiting PKCδ and subsequent activation of the RIPK1-RIPK3-MLKL necroptotic
pathway, to which has been shown to have positive therapeutic benefits previously29.
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Therefore, current inhibitors for the RIPK1-RIPK3-MLKL necroptotic pathway like Necrostatin-1
(RIPK1 kinase inhibitor), HS-1371 (RIPK3 inhibitor), GW806742X (MLKL inhibitor) could be
effective in the clinical treatment of necroptotic cell death and ultimately in the treatment of
heart failure. Also, another lab has shown the reduction of Cops6 in human hearts and in
animal models for ARVD/C that confirmed the pathological relevance of these studies in heart
failure28. Although the researchers proposed an in-depth mechanism, they did not look at the
deneddylation activity, holocomplex levels, or necroptosis. Still, it is a conceivable and a
potential pathogenic factor within this disease since downregulation of any of the eight
canonical subunits of the CSN will disrupt the CSN holocomplex formation and cause loss of
Cullin deneddylation activity. Necroptosis is likely here but unknown. No published study
besides past work from our lab shows the novelty of CSN knockouts in hearts and the primary
link of necrosis, primarily necroptosis.
Besides the cardiovascular clinical implications, this study also has direct, immediate
implications in the cancer field. Because the activity of CRLs plays a critical and diverse role in
cell cycle progression, gene transcription, apoptosis, signal transduction, and DNA replication,
aberrant CRL activity is frequently associated with tumor cell division and survival7. Accordingly,
the RING components of CRLs, RBX1 and RBX2 are known oncogenes that are commonly
overexpressed in several human cancers65-67. Neddylation inhibitors that inhibit the activation
and activity of CRLs, like MLN4924, are currently in clinical trials to treat certain types of skin,
blood, and bone marrow cancers by suppressing proliferation and metastasis7, 68. Consistently,
Cops5 is overexpressed in various primary tumors and overexpression of Cops5 causes p53
degradation leading to apoptosis resistance which is a classic hallmark of cancer69. Accordingly,
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a potent and selective inhibitor of Cops5, CSN5i-3, has become increasing popular in
chemotherapeutics. However, past research from this lab20, as well as this current study
directly caution the use of deneddylation or CSN inhibitors (trapping CRLs in a
neddylated/deneddylated state), precisely due to the dramatic and rapid cardiotoxic effects.
This study shows how cardiac function dramatically declines, reduces lifespan, and causes
massive cardiomyocyte necroptosis caused by Cops deficiency and disruption of the catalytic
dynamics. Although MLN4924 and CSN5i-3 show great promise in treating cancers, the decision
to treat patients with these inhibitors needs to be weighed heavily since the cardiotoxic effects
could outweigh the chemotherapeutic benefits; if treatment with these inhibitors is best, these
patients should be closely monitored for overall cardiac health.
4.4. Conclusions
The UPS is one of the two major protein degradation pathways in cells, and UPS abnormalities
have been implicated in a broad spectrum of human diseases. Since upwards of 80-90% of all
proteins will be regulated through the UPS, there are broad implications in virtually all signaling
pathways within the cell. Understanding the basic biology of this pathway and how critical
regulators of the UPS, like CRLs and the CSN, fit into this will be vital to exploring potential
therapeutic avenues to maintain or restore proteostasis for developing new therapeutic
strategies. Here we have demonstrated that (1) Cullin-deneddylation activity is required for the
CSN to suppress cardiomyocyte necrosis and (2) upregulation of PKCδ contributes to the
activation of the RIPK1-RIPK3-MLKL pathway by Cops8 deficiency in cardiomyocytes in mice.
Future research within this field will help our understanding of the molecular mechanisms
underlying cardiomyocyte cell death to slow or possibly prevent pathological cardiac
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remodeling and heart failure. A deeper understanding of what proteins manipulate the
necroptotic pathway, like potentially PKCδ, will aid in our therapeutic pursuits.
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5. LIMITATIONS
Limitations exist within this study, and future studies will need to be done to discover the
potential mechanisms at play here. 1) Within this study, only a couple of parameters were used
to examine necrosis, and more in-depth parameters will need to be detailed in future studies.
Extensive parameters like specialized markers of myocardial damage, cell viability, and cell
death should be used to verify these findings. Also, Cullin deneddylation activity is required to
suppress cardiomyocyte necrosis60, and the Cops8-cko, Cops5-cko, and Double-cko induce
similar necrosis suggesting a shared phenotype. However, we didn’t examine the Cullin
deneddylation levels between the cko mouse models or if the necrosis noticed in the Cops5-cko
and Double-cko is due to necroptosis, which remains to be confirmed. 2) Important conclusions
drawn from this study using two different types of models, a perinatal and an adult inducible
model, which both have potential drawbacks. The adult, inducible mouse model uses tamoxifen
chow, which is known to have cardiotoxic effects in itself70. Some cardiotoxic effects were seen
in the echocardiograms; however, no experimental or controls animals died from the current
dosage used, and experimental animals were compared to appropriate controls tested at the
same time to address this limitation and to reduce its’ impact.
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6. FUTURE DIRECTIONS
Many studies need to be completed to enrich our current understanding of the necroptotic cell
death pathway within cardiomyocytes. 1) Because Cops5-cko and Double-cko mice develop
cardiac pathology before Cops8-cko, it will also be essential to discover the exact mechanism as
to why this is (Cops5 additional functions outside of holocomplex, protein turnover differences
between Cops8 and Cops5, etc.). 2) At this moment, we have not examined Cullin
deneddylation in Cops5-cko. It is also not known whether the necrosis noticed in the Cops5-cko
and Double-cko mice belongs to necroptosis or whether other types of regulated necrosis might
be coming into play (ferroptosis, pyroptosis, etc.). 3) More extensive parameters like Creatine
Kinase MB (CK-MB), cardiac troponin I (cTnl), lactate dehydrogenase (LDH) release assays, as
well as inflammatory cytokines panels (TNFα, IL6, …) should be used to verify the findings of this
study. 4) It will also be essential to find the molecular link between PKCδ and the canonical
pathway to necroptosis.
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LIST OF ABBREVIATIONS AND ACRONYMS
CSN:

COP9 signalosome

UPS:

Ubiquitin-Proteasome System

CRLs:

Cullin Ring Ligases

ARVD/C:

Arrythmogenic Right Ventricular Dysplasia/Cardiomyopathy

ALP:

Autophagic-Lysosomal Pathway

PQC:

Protein Quality Control

cko

Cardiomyocyte-restricted knockout

Cops8-cko:

cko of the Cops8 gene

Cops5-cko:

cko of the Cops5 gene

Double-cko:

cko of both the Cops8 and the Cops5 gene

CTL:

Control group

MCM:

MerCreMer, mutant estrogen receptor sandwiched Cre

EBD:

Evans Blue Dye

PKC:

Protein kinase C

PRKCD:

The gene encoding the δ isoform of PKC

LV:

Left Ventricle

HR:

Heart Rate

EF:

Ejection Fraction

FS:

Fractional Shortening

SV:

Stroke Volume

CO:

Cardiac Output

LVPW;s:

End-Systolic Left Ventricular Posterior Wall Thickness

LVPW;d:

End-Diastolic Left Ventricular Posterior Wall Thickness

LVAW;s

End-Systolic Left Ventricular Anterior Wall Thickness

LVAW;d

End-Diastolic Left Ventricular Anterior Wall Thickness
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LVID;s:

End-Systolic Left Ventricular Internal Diameter

LVID;d:

End-Diastolic Left Ventricular Internal Diameter

ESV:

End-Systolic Volume

EDV:

End-Diastolic Volume

pS166-RIPK1:

Ser166-Phosphorylated RIPK1

pS321-RIPK1:

Ser321-Phosphorylated RIPK1

pS345-MLKL:

Ser345-phosphorylated MLKL

47

REFERENCES
1.
Wang X and Robbins J. Heart Failure and Protein Quality Control. Circ Res. 2006;99:1315-1328.
2.
Mearini G, Schlossarek S, Willis MS and Carrier L. The ubiquitin–proteasome system in cardiac
dysfunction. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2008;1782:749-763.
3.
Su H and Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control
perspective. Cardiovasc Res. 2010;85:253-62.
4.
Willis MS, Townley-Tilson WH, Kang EY, Homeister JW and Patterson C. Sent to destroy: the
ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular
development and disease. Circ Res. 2010;106:463-78.
5.
Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL. Inhibitors of
the proteasome block the degradation of most cell proteins and the generation of peptides presented
on MHC class I molecules. Cell. 1994;78:761-771.
6.
Wei N and Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol. 2003;19:261-86.
7.
Zhao Y and Sun Y. Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des.
2013;19:3215-25.
8.
Wei N, Serino G and Deng X-W. The COP9 signalosome: more than a protease. Trends in
Biochemical Sciences. 2008;33:592-600.
9.
Wei N and Deng XW. Characterization and purification of the mammalian COP9 complex, a
conserved nuclear regulator initially identified as a repressor of photomorphogenesis in higher plants.
Photochemistry and photobiology. 1998;68:237-41.
10.
Wei N, Chamovitz DA and Deng X-W. Arabidopsis COP9 is a component of a novel signaling
complex mediating light control of development. Cell. 1994;78:117-124.
11.
Lingaraju GM, Bunker RD, Cavadini S, Hess D, Hassiepen U, Renatus M, Fischer ES and Thomä
NH. Crystal structure of the human COP9 signalosome. Nature. 2014;512:161-165.
12.
He Q, Cheng P, He Q and Liu Y. The COP9 signalosome regulates the Neurospora circadian clock
by controlling the stability of the SCFFWD-1 complex. Genes Dev. 2005;19:1518-31.
13.
Wee S, Geyer RK, Toda T and Wolf DA. CSN facilitates Cullin-RING ubiquitin ligase function by
counteracting autocatalytic adapter instability. Nat Cell Biol. 2005;7:387-91.
14.
Denti S, Fernandez-Sanchez ME, Rogge L and Bianchi E. The COP9 signalosome regulates Skp2
levels and proliferation of human cells. J Biol Chem. 2006;281:32188-96.
15.
Lewno MT, Cui T and Wang X. Cullin Deneddylation Suppresses the Necroptotic Pathway in
Cardiomyocytes. Frontiers in Physiology. 2021;12:895.
16.
Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin
DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A,
Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T,
Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB and Langston SP. An
inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732-736.
17.
Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC
and Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. The Journal of Clinical
Investigation. 2003;111:1497-1504.
18.
Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BHL, Hewett TE,
Robbins J, Houser SR and Molkentin JD. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as
a primary mediator of heart failure. The Journal of Clinical Investigation. 2007;117:2431-2444.
19.
Li J, Zhang D, Wiersma M and Brundel B. Role of Autophagy in Proteostasis: Friend and Foe in
Cardiac Diseases. Cells. 2018;7.

48

20.
Su H, Li J, Menon S, Liu J, Kumarapeli AR, Wei N and Wang X. Perturbation of cullin
deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes
cardiomyocyte necrosis and dilated cardiomyopathy in mice. Circ Res. 2011;108:40-50.
21.
Su H, Li F, Ranek MJ, Wei N and Wang X. COP9 Signalosome Regulates Autophagosome
Maturation. Circulation. 2011;124:2117-2128.
22.
Su H, Li J, Osinska H, Li F, Robbins J, Liu J, Wei N and Wang X. The COP9 signalosome is required
for autophagy, proteasome-mediated proteolysis, and cardiomyocyte survival in adult mice. Circ Heart
Fail. 2013;6:1049-1057.
23.
Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S and Kato J-y. Multiple Functions of Jab1
Are Required for Early Embryonic Development and Growth Potential in Mice*. Journal of Biological
Chemistry. 2004;279:43013-43018.
24.
Schlierf A, Altmann E, Quancard J, Jefferson AB, Assenberg R, Renatus M, Jones M, Hassiepen U,
Schaefer M, Kiffe M, Weiss A, Wiesmann C, Sedrani R, Eder J and Martoglio B. Targeted inhibition of the
COP9 signalosome for treatment of cancer. Nature Communications. 2016;7:13166.
25.
Ranek MJ, Zheng H, Huang W, Kumarapeli AR, Li J, Liu J and Wang X. Genetically induced
moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during
systolic overload. J Mol Cell Cardiol. 2015;85:273-281.
26.
Tian Z, Zheng H, Li J, Li Y, Su H and Wang X. Genetically induced moderate inhibition of the
proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res.
2012;111:532-42.
27.
Chen SN, Czernuszewicz G, Tan Y, Lombardi R, Jin J, Willerson JT and Marian AJ. Human
molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a
novel gene for human hypertrophic cardiomyopathy. Circulation research. 2012;111:907-19.
28.
Liang Y, Lyon RC, Pellman J, Bradford WH, Lange S, Bogomolovas J, Dalton ND, Gu Y, Bobar M,
Lee M-H, Iwakuma T, Nigam V, Asimaki A, Scheinman M, Peterson KL and Sheikh F. Desmosomal COP9
regulates proteome degradation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. The
Journal of Clinical Investigation. 2021;131.
29.
Xiao P, Wang C, Li J, Su H, Yang L, Wu P, Lewno MT, Liu J and Wang X. COP9 Signalosome
Suppresses RIPK1-RIPK3-Mediated Cardiomyocyte Necroptosis in Mice. Circ Heart Fail.
2020;13:e006996.
30.
Liu J, Su H and Wang X. The COP9 signalosome coerces autophagy and the ubiquitin-proteasome
system to police the heart. Autophagy. 2016;12:601-2.
31.
Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular
regulation. Nature. 1988;334:661-5.
32.
Steinberg SF, Goldberg M and Rybin VO. Protein kinase C isoform diversity in the heart. J Mol
Cell Cardiol. 1995;27:141-53.
33.
Hayashi A, Seki N, Hattori A, Kozuma S and Saito T. PKCν, a new member of the protein kinase C
family, composes a fourth subfamily with PKCμ1The nucleotide sequence data reported in this paper
have been deposited in the DDBJ, EMBL and GenBank databases under the accession number
AB015982.1. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1999;1450:99-106.
34.
Malhotra A, Kang BP, Opawumi D, Belizaire W and Meggs LG. Molecular biology of protein
kinase C signaling in cardiac myocytes. Molecular and cellular biochemistry. 2001;225:97-107.
35.
Duquesnes N, Lezoualc'h F and Crozatier B. PKC-delta and PKC-epsilon: Foes of the same family
or strangers? Journal of Molecular and Cellular Cardiology. 2011;51:665-673.
36.
Erdbrügger W, Keffel J, Knocks M, Otto T, Philipp T and Michel MC. Protein kinase C isoenzymes
in rat and human cardiovascular tissues. British Journal of Pharmacology. 1997;120:177-186.

49

37.
Watanabe T, Ono Y, Taniyama Y, Hazama K, Igarashi K, Ogita K, Kikkawa U and Nishizuka Y. Cell
division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-delta subspecies.
Proc Natl Acad Sci U S A. 1992;89:10159-63.
38.
Li L, Lorenzo PS, Bogi K, Blumberg PM and Yuspa SH. Protein kinase Cdelta targets mitochondria,
alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes
when overexpressed by an adenoviral vector. Molecular and cellular biology. 1999;19:8547-58.
39.
Sumitomo M, Ohba M, Asakuma J, Asano T, Kuroki T, Asano T and Hayakawa M. Protein kinase
Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J Clin Invest.
2002;109:827-36.
40.
Churchill EN and Mochly-Rosen D. The roles of PKCδ and ϵ isoenzymes in the regulation of
myocardial ischaemia/reperfusion injury. Biochemical Society Transactions. 2007;35:1040-1042.
41.
Johnson JA and Mochly-Rosen D. Inhibition of the spontaneous rate of contraction of neonatal
cardiac myocytes by protein kinase C isozymes. A putative role for the epsilon isozyme. Circulation
research. 1995;76:654-63.
42.
Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, Murphy E and
Mochly-Rosen D. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic
heart in vivo. Circulation. 2003;108:2304-7.
43.
Inagaki K, Hahn HS, Dorn GW, 2nd and Mochly-Rosen D. Additive protection of the ischemic
heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C
activator. Circulation. 2003;108:869-75.
44.
Menon S, Chi H, Zhang H, Deng XW, Flavell RA and Wei N. COP9 signalosome subunit 8 is
essential for peripheral T cell homeostasis and antigen receptor-induced entry into the cell cycle from
quiescence. Nat Immunol. 2007;8:1236-45.
45.
Panattoni M, Sanvito F, Basso V, Doglioni C, Casorati G, Montini E, Bender JR, Mondino A and
Pardi R. Targeted inactivation of the COP9 signalosome impairs multiple stagesof T cell development.
Journal of Experimental Medicine. 2008;205:465-477.
46.
Sitte S, Gläsner J, Jellusova J, Weisel F, Panattoni M, Pardi R and Gessner A. JAB1 Is Essential for
B Cell Development and Germinal Center Formation and Inversely Regulates Fas Ligand and Bcl6
Expression. The Journal of Immunology. 2012;188:2677.
47.
Porrello E, Rivellini C, Dina G, Triolo D, Del Carro U, Ungaro D, Panattoni M, Feltri ML, Wrabetz L,
Pardi R, Quattrini A and Previtali SC. Jab1 regulates Schwann cell proliferation and axonal sorting
through p27. Journal of Experimental Medicine. 2013;211:29-43.
48.
Panattoni M, Maiorino L, Lukacs A, Zentilin L, Mazza D, Sanvito F, Sitia G, Guidotti LG and Pardi
R. The COP9 signalosome is a repressor of replicative stress responses and polyploidization in the
regenerating liver. Hepatology. 2014;59:2331-43.
49.
Chou W-H, Choi D-S, Zhang H, Mu D, McMahon T, Kharazia VN, Lowell CA, Ferriero DM and
Messing RO. Neutrophil protein kinase Cδ as a mediator of stroke-reperfusion injury. The Journal of
Clinical Investigation. 2004;114:49-56.
50.
Ahmad F, Lal H, Zhou J, Vagnozzi RJ, Yu JE, Shang X, Woodgett JR, Gao E and Force T.
Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile
dysfunction, and heart failure. Journal of the American College of Cardiology. 2014;64:696-706.
51.
Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM and
Molkentin JD. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic
heart using a tamoxifen-inducible Cre protein. Circ Res. 2001;89:20-5.
52.
Chopra A, Willmore WG and Biggar KK. Protein quantification and visualization via ultravioletdependent labeling with 2,2,2-trichloroethanol. Scientific Reports. 2019;9:13923.

50

53.
Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J
and Molkentin JD. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis
attenuates muscular dystrophy. Nat Med. 2008;14:442-7.
54.
Hu C, Tian Y, Xu H, Pan B, Terpstra EM, Wu P, Wang H, Li F, Liu J and Wang X. Inadequate
ubiquitination-proteasome coupling contributes to myocardial ischemia-reperfusion injury. The Journal
of Clinical Investigation. 2018;128:5294-5306.
55.
Busch S, Schwier EU, Nahlik K, Bayram O, Helmstaedt K, Draht OW, Krappmann S, Valerius O,
Lipscomb WN and Braus GH. An eight-subunit COP9 signalosome with an intact JAMM motif is required
for fungal fruit body formation. Proceedings of the National Academy of Sciences of the United States of
America. 2007;104:8089-94.
56.
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz
MA and Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic
brain injury. Nature chemical biology. 2005;1:112-9.
57.
Huppi K, Siwarski D, Goodnight J and Mischak H. Assignment of the protein kinase C delta
polypeptide gene (PRKCD) to human chromosome 3 and mouse chromosome 14. Genomics.
1994;19:161-2.
58.
Yoshida K, Wang HG, Miki Y and Kufe D. Protein kinase Cdelta is responsible for constitutive and
DNA damage-induced phosphorylation of Rad9. Embo j. 2003;22:1431-41.
59.
Joseph LC, Reyes MV, Lakkadi KR, Gowen BH, Hasko G, Drosatos K and Morrow JP. PKCδ causes
sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction. Am J Physiol Heart Circ Physiol.
2020;318:H778-h786.
60.
Xiao P, Wang C, Li J, Su H, Yang L, Wu P, Lewno Megan T, Liu J and Wang X. COP9 Signalosome
Suppresses RIPK1-RIPK3–Mediated Cardiomyocyte Necroptosis in Mice. Circulation: Heart Failure.
2020;13:e006996.
61.
Jaco I, Annibaldi A, Lalaoui N, Wilson R, Tenev T, Laurien L, Kim C, Jamal K, Wicky John S, Liccardi
G, Chau D, Murphy JM, Brumatti G, Feltham R, Pasparakis M, Silke J and Meier P. MK2 Phosphorylates
RIPK1 to Prevent TNF-Induced Cell Death. Mol Cell. 2017;66:698-710.e5.
62.
Wang Q, Liu Z, Ren J, Morgan S, Assa C and Liu B. Receptor-interacting protein kinase 3
contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ Res.
2015;116:600-11.
63.
Wang X and Cui T. Autophagy modulation: a potential therapeutic approach in cardiac
hypertrophy. Am J Physiol Heart Circ Physiol. 2017;313:H304-H319.
64.
Wang X and Robbins J. Proteasomal and lysosomal protein degradation and heart disease. J Mol
Cell Cardiol. 2014;71:16-24.
65.
Wei D and Sun Y. Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The
Role in Cancer and as Cancer Targets. Genes Cancer. 2010;1:700-7.
66.
Jia L and Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets.
2011;11:347-56.
67.
Jia L, Soengas MS and Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell
growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009;69:497482.
68.
Tong S, Si Y, Yu H, Zhang L, Xie P and Jiang W. MLN4924 (Pevonedistat), a protein neddylation
inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma. Scientific
Reports. 2017;7:5599.
69.
Zhang XC, Chen J, Su CH, Yang HY and Lee MH. Roles for CSN5 in control of p53/MDM2 activities.
J Cell Biochem. 2008;103:1219-30.

51

70.
Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, Gabrielson KL, Takimoto E and Kass DA.
Avoidance of Transient Cardiomyopathy in Cardiomyocyte-Targeted Tamoxifen-Induced MerCreMer
Gene Deletion Models. Circ Res. 2009;105:12-15.

52

